(24/7 MARKET NEWS) – Biophytis SA (NASDAQ:BPTS) and Skyepharma, a French pharmaceutical company, stated, this morning, that they signed a partnership agreement for the production of regulatory batches of Sarconeos (BIO101) for severe forms of Covid-19, to submit for marketing authorization applications.
Biophytis is trading at $1.19, up $0.3009 (+35.21%), on 1.25M premarket shares traded.
Its 52-week range is $0.8801 to $9.024. The gap from $1.28 to $1.38 should refill and most of its resistance is low volume, so this may have legs today.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
